Deutsches Krebsforschungszentrum; Stiftung des öffentlichen Rechts
发明人:
申请号：
EP19155958.2
公开号：
EP3693740A1
申请日:
2019.02.07
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention provides an improved class of dithiocarbamate complexes with increased tumour spheroid activity. The invention provides the novel compounds as such, and their medical application for the treatment of tumour diseases. The compounds of the invention are surprisingly effective compared to the prior art dithiocarbamates, in particular with respect to tumour spheroids. Another aspect of the herein described invention provides a diagnostic determination of tumours with increased susceptibility to a treatment with the dithiocarbamates of the invention. This aspect of the invention suggests determining components of the thioredoxin 1 (TRX1)/thioredoxin reductase 1 (TRXR1) system as an indicator of treatment responders. In context of this inventive aspect, the dithiocarbamate compounds of the invention were identified as competitive TRXR1 binders, and hence, the TRX1-amount in tumours is an important factor for treatment success.
